{"id":"fluorometholone-0-1-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Cataract formation (with prolonged use)"},{"rate":null,"effect":"Local irritation or stinging"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Secondary ocular infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluorometholone reduces inflammation by inhibiting the production of inflammatory mediators and suppressing immune cell activity in ocular tissues. It decreases vasodilation, edema, and cellular infiltration characteristic of inflammatory eye conditions. The drug is applied topically to the eye where it exerts local anti-inflammatory effects with minimal systemic absorption.","oneSentence":"Fluorometholone is a topical corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:39.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and allergic conditions of the eye including conjunctivitis, keratitis, and iritis"},{"name":"Post-operative inflammation following ocular surgery"},{"name":"Corneal injury and inflammation"}]},"trialDetails":[{"nctId":"NCT04149210","phase":"PHASE3","title":"FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-08-19","conditions":"Trachomatous Trichiasis (TT), Eye Diseases, Eyelid Diseases","enrollment":2410},{"nctId":"NCT06876116","phase":"PHASE4","title":"Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2022-09-01","conditions":"Dry Eye Disease (DED)","enrollment":32},{"nctId":"NCT06498440","phase":"PHASE4","title":"Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT","status":"NOT_YET_RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2024-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension, Postoperative Inflammation","enrollment":126},{"nctId":"NCT06209879","phase":"PHASE4","title":"Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-02-05","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT05771194","phase":"PHASE4","title":"Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2021-02-01","conditions":"Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid","enrollment":40},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":"Corneal Epithelial Wound","enrollment":250},{"nctId":"NCT05131152","phase":"NA","title":"Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2021-12-01","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT05011916","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2021-08-10","conditions":"Corneal Neovascularization","enrollment":60},{"nctId":"NCT04376970","phase":"PHASE4","title":"Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Military Hospital of Tunis","startDate":"2017-04-01","conditions":"Adenoviral Keratoconjunctivitis","enrollment":51},{"nctId":"NCT01949454","phase":"NA","title":"Fluorometholone as Ancillary Therapy for TT Surgery","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-11","conditions":"Trichiasis, Trachoma, Bilamellar Tarsal Rotation","enrollment":154},{"nctId":"NCT02051023","phase":"PHASE3","title":"Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2014-02","conditions":"Dry Eye","enrollment":41},{"nctId":"NCT01448213","phase":"PHASE2","title":"Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)","status":"COMPLETED","sponsor":"Price Vision Group","startDate":"2011-10","conditions":"Fuchs' Dystrophy, Bullous Keratopathy","enrollment":264},{"nctId":"NCT02011776","phase":"","title":"A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome","status":"COMPLETED","sponsor":"Santen Pharmaceutical(China) Co.,LTD","startDate":"2013-03","conditions":"Dry Eye Syndromes, Sjögren Syndrome","enrollment":35},{"nctId":"NCT01288404","phase":"NA","title":"Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2008-01","conditions":"Pterygium of the Conjunctiva and Cornea","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fluorometholone 0.1% ophthalmic solution","genericName":"Fluorometholone 0.1% ophthalmic solution","companyName":"University of Pennsylvania","companyId":"university-of-pennsylvania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluorometholone 0.1% ophthalmic solution is a glucocorticoid receptor agonist, classified as a small molecule. It has been studied for various eye conditions, including dry eye syndromes, Sjögren Syndrome, and pterygium of the conjunctiva and cornea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}